ATS leads €65m Series D round for German biotech firm

Ganymed pharmaceutical has now raised €117m from mostly German private equity firms to develop its cancer drugs pipeline.

5 January 2013•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

ATS leads &euro;65m Series D round for German biotech firm